TRIVITRON INKS A STRATEGIC ALLIANCE WITH C-CAMP, AN INITIAITVE WITH DEPARTMENT OF BIOTECHNOLOGY, GOVERNMENT OF INDIA

Trivitron Healthcare Private Limited, a leading medical device company providing affordable healthcare solutions to the healthcare industry, has entered into a strategic partnership by signing a Memorandum of Association (MoU) with the Centre for Cellular And Molecular Platforms (C-CAMP),an initiative of the Department of Biotechnology, Ministry of Science and Technology and Earth Sciences, Govt. of India. This partnership is a strategic step for both Trivitron and C-CAMP towards co-development of world-class healthcare technologies completely indigenously under “Joint Intellectual Properties” (i.e. product and process patents and know-how) aegis.

The MoU was signed in the presence of Dr. Renu Swarup, Secretary, Department of Biotechnology, Ministry of Science and Technology, Government of India & Chairperson, Biotechnology Industry Research Assistance Council (BIRAC); Dr. Taslimarif Saiyed, CEO & Director, C-CAMP; and Dr. G. S. K. Velu, Chairman & Managing Director, Trivitron Healthcare Private Limited.

C-CAMP has developed and tested an indigenous multiplex fluorescent microfluidic-analyser, covered under two patents; a base-patent for microfluidics flow analyser, which is filed and granted in several geographies, and a follow-on patent covering multiplex functionality. C-CAMP will demonstrate proof of concept and will participate in the co-development of a biological fluid analyser for clinical diagnostics. By the MoU, Trivitron which has a history of developing and installing diagnostic devices, including imaging devices globally is expected to facilitate these C-CAMP developed technologies in reaching a wider market segment commercially.

Confirming the development, Dr. Taslimarif Saiyed, CEO & Director, C-CAMP said, “The MoU between C-CAMP and Trivitron would mark a new beginning in the healthcare space with emergence of ground breaking technologies from India developed completely indigenously. This effort would be the first step from India in this direction. Our technology will be in line with international healthcare technological trends and there will be joint work on arriving at product specifications and requirements for commercially and clinically viable devices. The tie up will not only facilitate the technology but also manufacturing of associated devices taking into consideration the desired cost-effectiveness and requirements for commercial viability.”

Speaking on the occasion, Dr. G. S. K. Velu said“We are delighted to be partnering withC-CAMP. They are today among India’s most exciting and unique life sciences innovation hubs that brings together academia, industry and the startup ecosystem on one platform. India is today witnessing massive development in the healthcare space, opening avenues for new advancements and innovations. As a medical technology company providing affordable healthcare solutions, Trivitron constantly pursues technological innovations to offer superior, and yet cost-effective clinical benefits. The alliance with C-CAMP is in line with this endeavour and we are confident that C-CAMP’s culture of innovation and excellence will enable us to provide technologically more advanced devices for enhanced diagnosis and treatments.”

Trivitron will also work along with C-Camp to co-develop other relevant technologies and devices in the fields of point-of-care testing, microfluidics, and multiplex detection, which are within the domain of expertise and of strategic interest to Trivitron & C-Camp.

About C-CAMP:

The Centre for Cellular and Molecular Platforms (C-CAMP) is an initiative of the Department of Biotechnology, Ministry of Science and Technology and Earth Sciences, Govt. of India, with a mandate to enable cutting edge Life Sciences and Healthcare Research and Innovation. It is one of the country’s most exciting and unique life sciences innovation hubs bringing together academia, industry and the startup ecosystem all on one platform. It is also a part of one of the country’s earliest Bio Clusters – the Bangalore Life Sciences Cluster (BLiSC) – comprising of National Centre for Biological Sciences (NCBS) and Institute for Stem Cell Biology and Regenerative Medicine (inStem) and C-CAMP.

About Trivitron Healthcare:

Since 1997, the journey of Trivitron Healthcare as a medical technology company providing affordable healthcare solutions weaves a fascinating thread of inspiration to many healthcare providers. Having a solid expertise in research and development, Trivitron manufactures and distributes exceptional medical technology products to 180 countries. With 9 USFDA, CE certified manufacturing facilities; Trivitron spearheads innovation in the fields of Newborn Screening, In-Vitro Diagnostics, Imaging & Radiology, Radiation Protection, Critical Care and Operating Room Solutions, thus, engraving its name as a holistic healthcare provider.

admin

Recent Posts

Breaking the Glass Ceiling: How a US MBA Elevates Career Trajectories

In the world of business, reaching the pinnacle of success often feels like a journey…

12 months ago

India, UAE sign MoU to strengthen ties in education sector

The MoU aims at facilitating student and faculty mobility, joint research programmes, designing courses, organising…

1 year ago

SPARSH Hospital Conducts Stroke Awareness Campaign titled

Bangalore, October 30, 2023 –In commemoration of World Stroke Day, SPARSH Hospital, RR Nagar, orchestrated a…

1 year ago

MGM Cancer Institute Making Strides for Breast Cancer

Chennai, 28th Oct 2023: MGM Cancer Institute, a leading healthcare facility dedicated to pioneering advancements…

1 year ago

Ancient landscape discovered beneath East Antarctic Ice Sheet

October 27, 2023:The research team, which also involved scientists at Durham University, used satellite data…

1 year ago

IIM Kashipur’s DIC Inks MoU with Atal Tinkering Lab to Promote Innovation, Creativity, and Entrepreneurship in Young Students

Kashipur, 19th October 2023: The Design Innovation Centre (DIC) of the Indian Institute of Management Kashipur signed…

1 year ago